Pediatric Precursor B-Cell Lymphoblastic Malignancies: From Extramedullary to Medullary Involvement.

B-cell acute lymphoblastic leukemia B-cell lymphoblastic lymphoma BCP-ALL BCP-LBL NHL disease spectrum non-Hodgkin lymphoma

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
12 Aug 2022
Historique:
received: 24 06 2022
revised: 22 07 2022
accepted: 10 08 2022
entrez: 26 8 2022
pubmed: 27 8 2022
medline: 27 8 2022
Statut: epublish

Résumé

B-cell lymphoblastic lymphoma (BCP-LBL) and B-cell acute lymphoblastic leukemia (BCP-ALL) are the malignant counterparts of immature B-cells. BCP-ALL is the most common hematological malignancy in childhood, while BCP-LBL accounts for only 1% of all hematological malignancies in children. Therefore, BCP-ALL has been well studied and treatment protocols have changed over the last decades, whereas treatment for BCP-LBL has stayed roughly the same. Clinical characteristics of 364 pediatric patients with precursor B-cell malignancies were studied, consisting of BCP-LBL (n = 210) and BCP-ALL (n = 154) patients. Our results indicate that based on the clinical presentation of disease, B-cell malignancies probably represent a spectrum ranging from complete isolated medullary disease to apparent complete extramedullary disease. Hepatosplenomegaly and peripheral blood involvement are the most important discriminators, as both seen in 80% and 95% of the BCP-ALL patients and in 2% of the BCP-LBL patients, respectively. In addition, we show that the overall survival rates in this cohort differ significantly between BCP-LBL and BCP-ALL patients aged 1−18 years (p = 0.0080), and that the outcome for infants (0−1 years) with BCP-LBL is significantly decreased compared to BCP-LBL patients of all other pediatric ages (p < 0.0001).

Identifiants

pubmed: 36010889
pii: cancers14163895
doi: 10.3390/cancers14163895
pmc: PMC9405801
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Foundation KiKa
ID : 393

Références

Cancer Genet Cytogenet. 2009 May;191(1):27-33
pubmed: 19389505
Leuk Lymphoma. 2020 Sep;61(9):2129-2135
pubmed: 32427530
Blood. 2010 Apr 22;115(16):3206-14
pubmed: 20154213
J Clin Oncol. 2019 Sep 1;37(25):2246-2256
pubmed: 31283407
Pediatr Blood Cancer. 2020 Sep;67(9):e28357
pubmed: 32469139
Pediatr Blood Cancer. 2016 Jul;63(7):1214-21
pubmed: 27037853
J Clin Oncol. 2016 Aug 1;34(22):2591-601
pubmed: 27269950
Lancet. 2013 Jun 1;381(9881):1943-55
pubmed: 23523389
Blood. 1986 Jan;67(1):135-40
pubmed: 2934104
J Clin Oncol. 2009 Jul 10;27(20):3363-9
pubmed: 19433688
Leukemia. 2021 Apr;35(4):1001-1011
pubmed: 32820270
Semin Oncol. 1980 Sep;7(3):332-9
pubmed: 7414342
Blood. 2008 May 1;111(9):4477-89
pubmed: 18285545
Int J Hematol. 2013 Jul;98(1):74-88
pubmed: 23702913
Haematologica. 2017 Dec;102(12):2086-2096
pubmed: 28983060
J Clin Oncol. 1985 Nov;3(11):1513-21
pubmed: 3863894
Lancet Oncol. 2013 Mar;14(3):199-209
pubmed: 23395119

Auteurs

Emma Kroeze (E)

Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.

Laura Arias Padilla (L)

NHL-BFM Study Center and Pediatric Hematology and Oncology, University Hospital Muenster, 48149 Muenster, Germany.

Max Bakker (M)

Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.

Judith M Boer (JM)

Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.

Melanie M Hagleitner (MM)

Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.

Birgit Burkhardt (B)

NHL-BFM Study Center and Pediatric Hematology and Oncology, University Hospital Muenster, 48149 Muenster, Germany.

Takeshi Mori (T)

Department of Hematology and Oncology, Hyogo Prefectural Kobe Children's Hospital, Kobe 650-0047, Japan.

Andishe Attarbaschi (A)

Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, 1090 Vienna, Austria.

Jaime Verdú-Amorós (J)

Pediatric Oncology Department, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain.

Marta Pillon (M)

Clinic of Pediatric Hemato-Oncology, Department of Women's and Children's Health, University of Padova, 46010 Padova, Italy.

Liliya Anderzhanova (L)

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, 117198 Moscow, Russia.

Edita Kabíčková (E)

Department of Pediatric Hematology and Oncology, Charles University, 2nd Medical School and University Hospital Motol, 150 06 Prague, Czech Republic.

Alan K S Chiang (AKS)

Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong.

Rejin Kebudi (R)

Division of Pediatric Hematology-Oncology, Istanbul University, Oncology Institute, 34452 İstanbul, Turkey.

Karin Mellgren (K)

Department of Pediatric Oncology, Sahlgrenska University Hospital, University of Gothenburg, 413 45 Gothenburg, Sweden.

Jelena Lazic (J)

Department for Hematology and Oncology, University Children's Hospital, University of Belgrade, 11000 Belgrade, Serbia.

Janez Jazbec (J)

Division of Pediatrics, Hematology and Oncology, University Medical Center Ljubljana, SI-1000 Ljubljana, Slovenia.

Jules P P Meijerink (JPP)

Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.

Auke Beishuizen (A)

Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
Erasmus Medical Center, Sophia Children's Hospital, 3015 CN Rotterdam, The Netherlands.

Jan L C Loeffen (JLC)

Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.

Classifications MeSH